Carlos Kamiya Matsuoka, M.D.

Peer-Reviewed Articles

1. Andrew Rodriguez 1, Carlos Kamiya-Matsuoka 1, Nazanin K Majd. The Role of Immunotherapy in the Treatment of Rare Central Nervous System Tumors. Curr Oncol 30(6):5279-5298, 2023. PMID: 37366884.
2. Rubino F, Schur S, McGovern SL, Kamiya-Matsuoka C, DeMonte F, Raza SM. Impact of salvage surgery with or without reirradiation for skull base meningiomas recurring after prior radiotherapy. J Neurosurg:1-12. e-Pub 2023. PMID: 36738459.
3. Ludford K, Ho WJ, Thomas JV, Raghav KPS, Murphy MB, Fleming ND, Lee MS, Smaglo BG, You YN, Tillman MM, Kamiya-Matsuoka C, Thirumurthi S, Messick C, Johnson B, Vilar E, Dasari A, Shin S, Hernandez A, Yuan X, Yang H, Foo WC, W Qiao, Maru D, Kopetz S, Overman MJ.. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. J Clin Oncol, 2023. e-Pub 2023. PMID: 36623241.
4. Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva M. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med 29(1):115-126, 2023. e-Pub 2023. PMID: 36658425.
5. de Groot J, Ott M, Wei J, Kassab C, Fang D, Najem H, O'Brien BJ, Weathers SP, Kamiya-Matsuoka C, Majd NK, Harrison RA, Fuller GN, Huse J, Long JP, Sawaya R, Rao G, MacDonald T, Priebe W, DeCuypere M, Heimberger AB. A First-in-Human Phase I Trial of the Oral p-STAT3 inhibitor WP1066 in Patients with Recurrent Malignant Glioma. CNS Oncology 11(2):CNS87, 2022. e-Pub 2022. PMID: 35575067.
6. Dono A, Alfaro-Munoz K, Yan Y, Lopez-Garcia CA, Soomro Z, Williford G, Takayasu T, Robell L, Majd N, de Groot J, Esquenazi Y, Kamiya-Matsuoka C, Ballester L.. Molecular, Histologic and Clinical Characteristics of Oligodendrogliomas: A Multi-institutional Retrospective Study. Neurosurgery 90(5):515-522, 2022. PMID: 35179134.
7. Muir M, Patel R, Traylor JI, Chaves de Almeida Bastos D, Kamiya-Matsuoka C, Li J, Rao G, Prabhu SS. Laser Interstitial Thermal Therapy for Newly Diagnosed Glioblastoma. Lasers Med Sci 37(3):1811-1820, 2022. e-Pub 2021. PMID: 34687390.
8. Upadhyay R, Khose S, Pokhylevych H, Paulino AC, McAleer MF, Ghia A, Li J, Yeboa DN, Loghin M, Harrison R, O'Brien B, Kamiya-Matsuoka C, De Groot J, Puduvalli VK, Tatsui C, Alvarez-Breckenridge C, Prabhu S, Rhines L, Zaky W, Lin F, Weinberg JS, Fuller G, Sandberg DI, Johnson JM, McGovern SL. Patterns of failure after radiation therapy in primary spinal high-grade gliomas: A single institutional analysis. Neurooncol Adv 4(1):vdac129, 2022. e-Pub 2022. PMID: 36128585.
9. Rubino F, Schur S, McGovern S, Kamiya-Matsuoka C, DeMonte F, Raza S.. Impact of Salvage Surgery and Re-irradiation for Radiation Failed Recurrent Skull Base Meningiomas. Open Works at MD Anderson, 2022.
10. Khan B, Kamiya-Matsuoka C, Lee S, Rahman M, Rao G.. Prolonged Survival After Laser Interstitial Thermal Therapy in Glioblastoma. Surg Neurol Int 12:228, 2021. PMID: 34221559.
11. Sinning M, Frelinghuysen M, Gallegos M, Cordova A, Paredes P, Vogel C, Sujima E, Kamiya-Matsuoka C, Valdivia F.. Outcome of patients with primary glioblastoma in Chile: Single center series. Ecancermedicalscience 15:1184, 2021. PMID: 33777177.
12. Nam JY, Gilbert A, Cachia D, Mandel J, Fuller GN, Penas-Prado M, de Groot J, Kamiya-Matsuoka C. Pineal parenchymal tumor of intermediate differentiation: a single-institution experience. Neurooncol Pract 7(6):613-619, 2020. e-Pub 2020. PMID: 33312675.
13. Majd N, Waguespack SG, Janku F, Fu S, Penas-Prado M, Xu M, Alshawa A, Kamiya-Matsuoka C, Raza SM, McCutcheon IE, Naing A.. Efficacy of Pembrolizumab in Patients with Pituitary Carcinoma: results from a phase II study. J Immunother Cancer 8(2), 2020. PMID: 33427689.
14. Anakwenze CP, McGovern S, Taku N, Liao K, Boyce-Fappiano DR, Kamiya-Matsuoka C, Ghia A, Chung C, Trifiletti D, Ferguson SD, Li J, Yeboa DN. Association Between Facility Volume and Overall Survival for Patients with Grade II Meningioma after Gross Total Resection. World Neurosurg 141:e133-e144, 2020. e-Pub 2020. PMID: 32407910.
15. Weathers SP, Penas-Prado M, Pei BL, Ling X, Kassab C, Banerjee P, Bdiwi M, Shaim H, Alsuliman A, Shanley M, de Groot JF, O'Brien BJ, Harrison R, Majd N, Kamiya-Matsuoka C, Fuller GN, Huse JT, Chi L, Rao G, Weinberg JS, Lang FF, Sawaya R, Shpall EJ, Rezvani K, Heimberger AB. Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. Clin Cancer Res 26(14):3565-3577, 2020. e-Pub 2020. PMID: 32299815.
16. de Groot J, Penas-Prado M, Alfaro-Munoz KD, Hunter K, Pei B, O'Brien B, Weathers SP, Loghin M, Kamiya-Matsuoka C, Yung WKA, Mandel J, Wu J, Yuan Y, Zhou S, Fuller GN, Huse J, Rao G, Weinberg JS, Prabhu SS, McCutcheon IE, Lang FF, Ferguson SD, Sawaya R, Colen R, Yadav SS, Blando J, Vence L, Allison J, Sharma P, Heimberger AB.. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol 22(4):539-549, 2020. PMID: 31755915.
17. Kamiya-Matsuoka C, Hamza MA, de Groot JF. Impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastoma. J Clin Neurosci 74:36-40, 2020. e-Pub 2020. PMID: 31982279.
18. Rafei H, Jabbour EJ, Kantarjian H, Sinicrope KD, Kamiya-Matsuoka C, Mehta RS, Daver NG, Kadia TM, Naqvi K, Cortes J, Konopleva M. Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series. Leuk Lymphoma 60(13):3292-3295, 2019. e-Pub 2019. PMID: 31246142.
19. Majd N, Kamiya-Matsuoka C, de Groot JF.. The path forward for anti-programed cell death-1 therapy in gliomas. Curr Opin Neurol 32(6):864-871, 2019. PMID: 31567548.
20. Baig M, Fuller G, Gupta S, Tran G, Mork M, Slopis J, Kamiya C, Khatua S, Zaky W, Sadighi Z.. Pdct-02. Unique concurrent association of somatic and germline nf1 mutations with germline mismatch repair mutations in pediatric glioblastoma multiforme. Neuro-Oncology 21(suppl 6):vi183, 2019.
21. Santos-Pinheiro F, Penas-Prado M, Kamiya-Matsuoka C, Waguespack SG, Mahajan A, Brown PD, Shah KB, Fuller GN, McCutcheon IE. Treatment and long-term outcomes in pituitary carcinoma: a cohort study. Eur J Endocrinol 181(4):397-407, 2019. PMID: 31349217.
22. Harrison RA, Anderson MD, Cachia D, Kamiya-Matsuoka C, Weathers SS, O'Brien BJ, Penas-Prado M, Yung WKA, Wu J, Yuan Y, de Groot JF.. Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center. Eur J Cancer 112:83-93, 2019. e-Pub 2019. PMID: 30951926.
23. D'Angelo F, Ceccarelli M, Tala , Garofano L, Zhang J, Frattini V, Caruso FP, Lewis G, Alfaro KD, Bauchet L, Berzero G, Cachia D, Cangiano M, Capelle L, de Groot J, DiMeco F, Ducray F, Farah W, Finocchiaro G, Goutagny S, Kamiya-Matsuoka C, Lavarino C, Loiseau H, Lorgis V, Marras CE, McCutcheon I, Nam DH, Ronchi S, Saletti V, Seizeur R, Slopis J, Suñol M, Vandenbos F, Varlet P, Vidaud D, Watts C, Tabar V, Reuss DE, Kim SK, Meyronet D, Mokhtari K, Salvador H, Bhat KP, Eoli M, Sanson M, Lasorella A, Iavarone A. The molecular landscape of glioma in patients with Neurofibromatosis 1. Nat Med 25(1):176-187, 2019. e-Pub 2018. PMID: 30531922.
24. Daher A, Kamiya-Matsuoka C, Loghin ME, Penas-Prado M, Tummala S.. Neuromuscular weakness syndromes from immune checkpoint inhibitors: A case series and literature review. J Immunother Precis Oncol 2(3):93-100, 2019.
25. Kassab C, Zamler D, Kamiya-Matsuoka C, Gatalica Z, Xiu J, Spetzler D, Heimberger AB. Genetic and immune profiling for potential therapeutic targets in adult human craniopharyngioma. Clin Oncol Res 2(3):2-8, 2019. e-Pub 2019. PMID: 31712784.
26. Daher A, Kamiya-Matsuoka C, Woodman K. Patient With 2 Hematologic Malignancies Presenting as Neurolymphomatosis. J Clin Neuromuscul Dis 19(3):124-130, 2018. PMID: 29465612.
27. Yust Katz S, Cachia D, Kamiya-Matsuoka C, Olar A, Theeler B, Penas Prado M, Gilbert MR, Armstrong T. Ependymomas arising outside of the central nervous system: A case series and literature review. J Clin Neurosci 47:202-207, 2018. e-Pub 2017. PMID: 29054328.
28. Cachia D, Elshafeey NA, Kamiya-Matsuoka C, Hatami M, Alfaro-Munoz KD, Mandel JJ, Colen R, de Groot JF.. Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients. Journal of Neuro-Oncology 135:75-81, 2017. e-Pub 2017. PMID: 28702781.
29. Kamiya-Matsuoka C, Tummala S. Electrographic patterns in patients with posterior reversible encephalopathy syndrome and seizures. J Neurol Sci 375:294-298, 2017. e-Pub 2017. PMID: 28320152.
30. Pinnix CC, Chi L, Jabbour EJ, Milgrom SA, Smith GL, Daver N, Garg N, Cykowski MD, Fuller G, Cachia D, Kamiya-Matsuoka C, Woodman K, Dinardo C, Jain N, Kadia TM, Pemmaraju N, Ohanian M, Konopleva M, Kantarjian HM, Dabaja BS.. Dorsal Column Myelopathy after Intrathecal Chemotherapy for Leukemia. Am J Hematol 92(2):155-160, 2017. e-Pub 2017. PMID: 27874212.
31. Kamiya-Matsuoka C, Cachia D, Waguespack SG, Crane CH, Mahajan A, Brown PD, Nam JY, McCutcheon IE, Penas-Prado M. Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma. Pituitary 19(4):415-21, 2016. PMID: 27106209.
32. Kamiya-Matsuoka C, Paker AM, Chi L, Youssef A, Tummala S, Loghin ME. Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study. J Neurooncol 128(1):75-84, 2016. e-Pub 2016. PMID: 26900076.
33. Liao B, Kamiya-Matsuoka C, Fang X, Smith RG, Shanina E. Alternating Ptosis Associated with Asialo-GM1 and GD1b Antibodies. Int J Neurosci:1-9. e-Pub 2015. PMID: 26710925.
34. Cachia D, Kamiya-Matsuoka C, Mandel JJ, Olar A, Cykowski MD, Armstrong TS, Fuller GN, Gilbert MR, De Groot JF. Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. J Neurooncol 125(2):401-10, 2015. e-Pub 2015. PMID: 26354773.
35. Rizk N, Kamiya-Matsuoka C, Tremont-Lukats IW. Lower Extremity Edema, Anxiety, and Cyanosis During Chemoradiation Therapy for Glioblastoma. JAMA Oncol:1-3. e-Pub 2015. PMID: 26540389.
36. Hamza MA, Kamiya-Matsuoka C, Liu D, Yuan Y, Puduvalli VK. Outcome of patients with malignant glioma and synchronous or metachronous non-central nervous system primary neoplasms. J Neurooncol. e-Pub 2015. PMID: 26566652.
37. Kamiya-Matsuoka C, Cachia D, Yust-Katz S, Rodriguez YA, Garciarena P, Rodarte EM, Tremont-Lukats IW. Ischemic stroke in patients with gliomas at The University of Texas-M.D. Anderson Cancer Center. J Neurooncol 125(1):143-8, 2015. e-Pub 2015. PMID: 26272599.
38. Bittar J, Kamiya-Matsuoka C, Barata PC, Lee-Kim SH, Olar A, Tremont-Lukats IW. Corticosteroid sensitivity in gliomatosis cerebri delays diagnosis. Pract Neurol 15(4):309-11, 2015. e-Pub 2015. PMID: 25922538.
39. Pachella LA, Kamiya-Matsuoka C, Lee EL, Olar A, Yung WK. Supratentorial extraventricular anaplastic ependymoma with extracranial metastasis. J Clin Neurosci 22(3):605-7, 2015. e-Pub 2014. PMID: 25455735.
40. Mella DB, Kamiya-Matsuoka C, Liao B, Tummala S, de Groot J. Recurrent encephaloclastic cyst induced by intraventricular topotecan. J Neurol Sci 349(1-2):52-3, 2015. e-Pub 2014. PMID: 25598491.
41. Liao B, Kamiya-Matsuoka C. Atypical isolated nuclear oculomotor nerve syndrome: a diagnostic challenge. BMJ Case Rep 2015, 2015. e-Pub 2015. PMID: 25694634.
42. Liao B, Rodriguez RM, Metrus NR, Kamiya-Matsuoka C. Pseudoabducens palsy mimicking myasthenia gravis. BMJ Case Rep 2015, 2015. e-Pub 2015. PMID: 25733096.
43. Cachia D, Kamiya-Matsuoka C, Pinnix CC, Chi L, Kantarjian HM, Cortes JE, Daver N, Woodman K.. Myelopathy following intrathecal chemotherapy in adults: a single institution experience. J Neurooncol 122(2):391-398, 2015. PMID: 25666482.
44. Liao B, Kamiya-Matsuoka C, Fang X, Smith RG. Refractory IgG4-related intracranial hypertrophic pachymeningitis responded to rituximab. Neurol Neuroimmunol Neuroinflamm 1(4):e41, 2014. e-Pub 2014. PMID: 25364775.
45. Liao B, Kamiya-Matsuoka C, Gong Y, Chen M, Wolf BA, Fowler NH. Primary natural killer/T-cell lymphoma presenting as leptomeningeal disease. J Neurol Sci 343(1-2):46-50, 2014. e-Pub 2014. PMID: 24880537.
46. Kamiya-Matsuoka C, Shroff S, Gildersleeve K, Hormozdi B, Manning JT, Woodman KH. Neurolymphomatosis: a case series of clinical manifestations, treatments, and outcomes. J Neurol Sci 343(1-2):144-8, 2014. e-Pub 2014. PMID: 24928074.
47. Shroff S, Kamiya-Matsuoka C, Woodman K. An unusual cause of cerebellar ataxia in an immunocompromised elderly patient. J Neurol Sci 340(1-2):218-20, 2014. e-Pub 2014. PMID: 24635888.
48. Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 16(4):589-93, 2014. e-Pub 2014. PMID: 24482447.
49. Kamiya-Matsuoka C, Blas-Boria D, Williams MD, Garciarena P, Tummala S, Tremont-Lukats IW. N-type calcium channel antibody-mediated paraneoplastic limbic encephalitis: a diagnostic challenge. J Neurol Sci 338(1-2):188-90, 2014. e-Pub 2014. PMID: 24462122.
50. Kamiya-Matsuoka C, Shroff S, Tatsui CE, Tremont-Lukats IW, Gilbert MR. Sinking skin flap syndrome in glioblastoma. BMJ Case Rep 2014, 2014. e-Pub 2014. PMID: 25398923.
51. Kamiya-Matsuoka C, Cachia D, Olar A, Armstrong TS, Gilbert MR.. Primary brain tumors and posterior reversible encephalopathy syndrome. . Neuro Oncol Pract 1(4):184-190, 2014. PMID: 26034631.
52. Munoz J, Kumar VA, Hamilton J, Pasche LJ, Langford LA, Taggart MW, Kamiya-Matsuoka C, Tummala S, Moulder S, Kurzrock R. Posterior reversible encephalopathy syndrome: more than meets the eye. J Clin Oncol 31(20):e360-3, 2013. e-Pub 2013. PMID: 23733774.
53. Kamiya-Matsuoka C, Garciarena P, Hesham AM, Tremont-Lukats IW, de Groot JF. B Lymphoblastic Leukemia/Lymphoma Presenting As Seventh Cranial Nerve Palsy. Neurol Clin Pract. Neurol Clin Pract 3(6):532-534, 2013. e-Pub 2013.

Invited Articles

1. Majd N, Kamiya-Matsuoka C, de Groot JF.. The path forward for anti-programed cell death-1 therapy in gliomas. Curr Opin Neurol 32(6):864-871, 2019. PMID: 31567548.
2. Kamiya-Matsuoka C, Gilbert MR. Treating recurrent glioblastoma: an update. CNS Oncol 4(2):91-104, 2015. PMID: 25768333.

Manuals, Teaching Aids, Other Teaching Publications

1. Kamiya C. Standardized Protocol: Lumbar Puncture and/or Intrathecal Chemotherapy Administration, for APNs and PAs, MDACC, 2019.

Other Articles

1. Inga E, Lopez G, Kamiya-Matsuoka C Biological accidents in medical students of the National. An Fac med 4(2):91-104, 2010.

Editorials

1. Inga E, Lopez G, Kamiya-Matsuoka C. Biological accidents in medical students of the National University of San Marcos: prevalence, mechanisms and risk factors. An Fac Med 71(1):37-42, 2010.

Abstracts

1. Gregory T, Knight S, Aaroe A, O'Brien BJ, Patel CB, Weathers SS, Majd N, Puduvalli VK, Kamiya-Matsuoka C.. Accelerated tumor progression among glioma patients after COVID-19 infection. J Clin Oncol 41(suppl 16), 2023.
2. Kamiya-Matsuoka C, Weathers SP, Harrison RA, Majd NK, Aaroe AE, Knight S, Hanna T, Gregory TA, Langlands J, Brown D, Puduvalli VK.. VAL-083 in patients with recurrent glioblastoma treated under expanded access program. Cancer Res 83(8 suppl):LB127, 2023.
3. Kamiya-Matsuoka C, Knight S, Hanna T, Gregory TA, Langlands J, Brown D, Puduvalli VK.. RELA fusion-positive ependymoma and diffuse midline glioma treated with VAL-083 under expanded access - case reports [abstract]. Cancer Res 83(8 suppl):LB126, 2023.
4. Gupta P, Dang M, Oberai S, Peshoff M, Milam N, Ahmed A, Bojja K, Tran TM, Cox K, Shehwana H, Kamiya Matsuoka C, Li J, Gumin J, Goldman A, Seth SA, Maheshwari A, Lang FF, Navin NE, Heimberger AB, Dwyer KC, Wang L, Bhat KP.. Immunophenotyping of human brain tumors reveals myeloid cell mediated anti-glioma axis. Cancer Res 83(7 suppl):669, 2023.
5. TA Yap, Daveer N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F.. Highlights from Recent Cancer Literature: Trial Results with OXPHOS Inhibitors. Cancer Res 83(6):805-806, 2023.
6. Gupta P, Dang M, Hao D, Bojja K, Tran T, Shehwana H, Kamiya-Matsuoka C, Li J, Audia A, Kassab C, Ott M, Gumin J, Alenazy S, Goldman A, Seth S, Maheshwari A, Balasubramaniyan V, Vaillant B, de Groot J, Lavarone A, Lang F, Navin N, Heimberger A, Wang L, Bhat K.. Immunophenotyping of brain tumors identifies interferon enriched phagocytes in human gliomas. Journal for ImmunoTherapy of Cancer, 2022.
7. Kamiya-Matsuoka C, Knight S, Langlands J, Brown D, Puduvalli V.. Recurrent RELA Fusion-Positive Ependymoma Treated with VAL-083 under Expanded Access. Neuro-Oncology 24(suppl 7):vii106, 2022.
8. Kamiya-Matsuoka C, Majd N, Harrison R, Knight S, Langlands J, Brown D, Puduvalli V.. VAL-083 in Patients with Recurrent Glioblastoma Treated under Expanded Access Program. Neuro-Oncology 24(suppl 7):vii107, 2022.
9. Dono A, Alfaro-Munoz K, Yan Y, Lopez-Garcia CA, Soomro Z, Williford G, Takayasu T, Robell L, Majd NK, de Groot JF, Esquenazi Y, Kamiya-Matsuoka c, Ballester LY.. Molecular, Histological, and Clinical Characteristics of Oligodendrogliomas: A Multi-Institutional Retrospective Study. Neurosurgery 90(5):515-522, 2022. PMID: 35179134.
10. Weathers SP, Knafl M, Parra E, Hernandez S, Solis L, Sanchez Espiridion B, Wistuba I, Futreal A, Maru D, Kamiya-Matsuoka C, Harrison R, Joseph V, Yun C, Darbonne W, Loghin M, Penas-Prado M, Majd N, Yung WKA, O'Brien B, Woodman S, DeGroot J.. Biomarker immune correlates in newly diagnosed glioblastoma (GBM) treated with atezolizumab in combination with temozolomide (TMZ) and radiation. Neuro Oncology 23(Suppl 6):vi49, 2021.
11. Upadhyay R, Khose S, Pokhylevych H, dela Cruz Paulino A, McAleer MF, Ghia A, Li J, Yeboa DN, Loghin M, Harrison R, O'Brien B, Kamiya-Matsuoka C, DeGroot J, Puduvalli V, Tatsui C, Prabhu S, Zaky W, Lin F, Weinberg J, Rhines L, Fuller G, Sandberg D, Johnson JM, McGovern S.. Role of Radiotherapy in Management of Primary Spinal High Grade Glioma: A single institution retrospective analysis. Neuro Oncology 23(Suppl 6):vi42-vi43, 2021.
12. Ou A, Lin H, Yuan Y, Bornstein C, Alfaro-Munoz K, Afshar-Kharghan V, Kamiya-Matsuoka C, Majd N.. Risk and burden of thromboembolic and hemorrhagic events in patients with malignant glioma receiving bevacizumab. Neuro Oncology 23(Suppl 6):vi148, 2021.
13. Ludford K, Singh Raghav KP, Blum Murphy MA, Fleming ND, Nelson DA, Lee MS, Smaglo BG, You YN, Tillman MM, Kamiya-Matsuoka C, Thirumurthi S, Messick C, Johnson B, Vilar Sanchez E, Dasari A, Thomas JV, Foo WC, Qiao W, Kopetz S, Overman MJ.. Neoadjuvant pembrolizumab in localized/locally advanced solid tumors with mismatch repair deficiency. Annals of Oncology 32(Suppl 5):S1210, 2021.
14. Gupta P, Dang M, Hao D, Bojja K, Tran TM, Shehwana H, Kamiya-Matsuoka C, Li J, Audia A, Kassab C, Ott M, Gumin J, Alenazy S, Goldman A, Seth SA, Maheshwari A, Balasubramaniyan V, Vaillant B, de Groot JF, Lang FF, Iavarone A, Navin NE, Heimberger AB, Wang L, Bhat KP .. OTME-23. Single-cell transcriptomic and epigenomic immune landscape of isocitrate dehydrogenase stratified human gliomas. Neurooncol Advances V3(Suppl 2), 2021.
15. Ludford K, Singh Raghav KP, Blum Murphy MA, Fleming ND, Nelson DA, Lee MS, Smaglo BG, You YN, Tillman MM, Kamiya-Matsuoka C, Thirumurthi S, Messick C, Johnson B, Vilar Sanchez E, Dasari A, Thomas JV, Foo WC, Qiao W, Kopetz S, Overman MJ.. Safety and Efficacy of Neoadjuvant Pembrolizumab in Mismatch Repair Deficient Localized/Locally Advanced Solid Tumors. Journal of Clinical Oncology 39(Suppl 15):2520, 2021.
16. O'Brien B, Penas-Prado M, Kamiya-Matsuoka C, Weathers SP, Yung WKA, Loghin M, Harrison R, Majd N, Knight S, Bacha J, Brown D, Johnson G, Langlands J, Schwartz R, Kanekal S, Steino A, Lopez L, DeGroot J.. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting. Neuro Oncology 23(Suppl 6):vi65, 2021.
17. O'Brien B, Kamiya-Matsuoka C, Weathers SP, Yung WKA, Loghin M, Harrison R, Majd N, Knight S, Yuan Y, Bacha J, Brown D, Steino A, Johnson G, Kanekal S, Langlands J, Lopez L, Schwartz R, Penas-Prado M, DeGroot J.. Phase 2 study of dianhydrogalactitol (VAL-083) inpatients with MGMT-unmethylated, bevacizumab-naivepatients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting. Caner Research 81(Suppl 13):CT238, 2021.
18. Gupta P, Dang M, Bojja K, Tran T, Shehwana H, Kamiya-Matsuoka C, Li J, Kassab C, Ott M, Gumin J, Maheshwari A, de Groot J, Lang F, Balasubramaniyan V, Navin N, Heimberger A, Wang L, Bhat K.. Transcriptionally defined immune contexture in human gliomas at single-cell resolution. Neuro Oncology 22(Suppl 2):ii112, 2020.
19. Aaroe A, D3CODE Team, Harrison R, Majd N, O’Brien B, Weathers SP, Loghin M, Kamiya-Matsuoka C, Yung WKA, de Groot J, Woodman K.. A Snapshot of the impact of COVID-19 on patient with nervous system tumors. Neuro Oncol 22(Suppl 2):ii27, 2020. e-Pub 2020.
20. Youssef M, Pham L, Demirhan M, Harrison R, Loghin M, Johnson J, Alfaro-Munoz K, Bhat K, Yeboa D, Prabhu S, Raza S, de Groot J, Demonte F, Kamiya-Matsuoka C.. Long-Term Use Of Everolimus Plus Octreotide For Recurrent Intracranial Or Spinal Meningioma: A Single Institution Experience. Neuro Oncol 22(Suppl 2):ii55, 2020. e-Pub 2020.
21. Dono A, Alfaro-Munoz K, Yan Y, Lopez-Garcia C, Soomro Z, Williford G, Takayasu T, Robell L, Majd N, de Groot J, Esquenazi Y, Kamiya-Matsuoka C, Ballester LY.. Molecular, histologic and clinical characteristics of oligodendrogliomas: A multi-institutional retrospective study. Neuro Oncol 22(Suppl 2):ii168, 2020.
22. Aaroe A, Dono A, Youssef M, Alfaro-Munoz K, Weathers SP, O’Brien B, Majd N, Harrison R, Loghin M, Soomro Z, Williford G, Fuller G, Yung WKA, Yeboa D, Esquenazi Y, Ballester LY, de Groot J, Kamiya-Matsuoka C.. A retrospective study of treatment strategies and outcomes in WHO grade II and III isocitrate dehydrogenase (IDH) wild-type astrocytoma. Neuro Oncol 22(Suppl):ii164-ii165, 2020.
23. Gupta P, Dang M, Bojja K, Tran T, Shehwana H, Kamiya-Matsuoka C, Li J, Kassab C, Ott M, Gumin J, Maheshwari A, de Groot J, Lang F, Balasubramaniyan V, Navin N, Heimberger A, Wang L, Bhat K.. Transcriptionally defined immune contexture in human gliomas at single-cell resolution. Neuro-Oncology Advances 22(suppl 2):ii112, 2020.
24. O’Brien B, de Groot JF, Kamiya-Matsuoka C, Weathers SP, Bacha J, Brown D, Steino A, Langlands J, Schwartz R, Kanekal S, Lopez L, Penas-Prado M.. Phase II Study of Dianhydrogalactitol (VAL-083) in Patients with Bevacizumab-Naïve Recurrent Glioblastoma, MGMT-Unmethylated. Cancer Research 80(16 Suppl), 2020.
25. Kamiya-Matsuoka C, Hamza MA, de Groot JF.. Impact of adverse effects of bevacizumab on survival outcomes of patients with recurrent glioblastoma. J Clin Neurosci 74:36-40, 2020. e-Pub 2020. PMID: 31982279.
26. Weathers SP, Penas-Prado M, Banerjee PP, Bdiwi M, Shaim H, Alsuliman A, Shanley M, Long J, de Groot JF, O'Brien BJ, Majd N, Harrison RA, Kamiya-Matsuoka C, Fuller GN, Chi L, Rao G, Lang FF, Shpall EJ, Rezvani,K, Heimberger AB.. A Phase I/II Clinical Trial of Autologous CMV-Specific T cells in Glioblastoma (GBM) Patients Reveals a Lack of Immune Effector Function. Journal of Clinical Oncology 38(Suppl 15), 2020.
27. Weathers SP, Kamiya-Matsuoka C, Harrison RA, Liu DD, Dervin S, Yun C, Loghin ME, Penas-Prado M, Majd N, Yung WKA, O'Brien BJ, de Groot JF.. Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM). Journal of Clinical Oncology 38(Suppl 15), 2020.
28. Weathers SP, Kamiya-Matsuoka C, Harrison R, Liu D, Sanqui E, Dervin S, Yun C, Loghin M, Penas-Prado M, Majd N, Yung WKA, O’Brien B, de Groot J.. Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (ATEZO) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM). Neuro Oncology 22(Suppl 2):ii35, 2020.
29. Majd N, Waguespack S, Filip J, Fu S, Penas-Prado M, Xu M, Alshawa A, Kamiya-Matsuoka C, Raza S, McCutcheon I, Aung N.. Efficacy of pembrolizumab in patients with pituitary carcinoma: Results from a Phase II study. Neuro Oncology 22(suppl 2), 2020.
30. O’Brien B, Penas-Prado M, Kamiya-Matsuoka C, Weathers SP, Yung WKA, Loghin M, Harrison R, Majd N, Bacha J, Brown D, Johnson G, Langlands J, Schwartz R, Kanekal S, Steino A, Lopez L, de Groot J.. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-Unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting. Neuro Oncol 22(2):ii59, 2020.
31. Kassab C, Zamler D, Kamiya-Matsuoka C, Gatalica Z, Xiu J, Spetzler D, Heimberger A.. Genetic and Immune Profiling for Potential Therapeutic Targets in Adult Human Craniopharyngioma. Clin Oncol Res 2(3):2-8, 2019. e-Pub 2019. PMID: 31712784.
32. Baig M, Fuller G, Gupta S, Tran G, Mork M, Slopis J, Kamiya-Matsuoka C, Khatua S, Zaky W, Sadighi Z.. Unique concurrent association of somatic and germline NF1 mutations with germline mismatch repair mutations in pediatric glioblastoma multiforme. Neuro Oncol 21(Suppl 6):vi183, 2019.
33. Metrus N, Kamiya-Matsuoka C, Weathers SP, Seligman C, O’Brien B.. Improvement of Leptomeningeal Disease Following Infectious Meningitis. Neuro Oncology 21(Suppl 6):vi59, 2019.
34. Kamiya-Matsuoka C, Metrus N, Weathers S, Ross J, Shaw KR, Penas-Prado M, Loghin ME, Alfaro-Munoz K, O'Brien BJ, Harrison R, Sadighi Z, Majd N, Yung WK, Meric-Bernstam F, Hambardzumyan D, de Groot J.. Is Immuno-Oncology Therapy Effective in Hypermutator Glioblastomas with Somatic or Germline mutations. Annals of Oncology 30(Suppl 5):V144, 2019.
35. Sinicrope KD, Barata P, Walker J, Tremont-Lukats IW, Groves M, Loghin M, Seligman C, Ferguson S, Weathers SP, Penas-Prado M, Kamiya-Matsuoka C, Harrison R, Tummala S, Trevino CR, Peinado S, Murthy RK, Seyedeh D, de Groot JF, O’Brien B.. Intrathecal Topotecan for Leptomeningeal Metastasis in Solid Tumors: The MD Anderson Experience. Neuro Oncology Advances 1(Suppl 1):i8, 2019.
36. Sinicrope KD, Barata P, Walker J, Tremont-Lukats IW, Groves M, Loghin M, Seligman C, Ferguson S, Weathers SP, Penas-Prado M, Kamiya-Matsuoka C, Harrison R, Tummala S, Trevino CR, Peinado S, Murthy RK, Seyedeh D, de Groot JF, O’Brien B. Intrathecal Topotecan for Leptomeningeal Metastasis in Solid Tumors: The MD Anderson Experience. Brain Metastasis research symposium, 2019.
37. O’Brien B, Penas-Prado M, Kamiya-Matsuoka C, Weathers SP, Yung WKA, Loghin M, Harrison R, Bacha J, Brown D, Johnson G, Langlands J, Schwartz R, Kanekal S, Lopez L, de Groot JF.. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting. Neuro Oncology 21(6):vi14-vi15, 2019.
38. Trevino CR, Murthy RK, Raghavendra AS, Loghin M, Seligman C, Ferguson S, Kamiya-Matsuoka C, Harrison R, Sinicrope KD, Valero V, Tummala S, Hess K, Tripathy D, de Groot JF, O’Brien B.. Intrathecal Trastuzumab plus/minus IT Topotecan for Patients with HER2+ Breast Cancer and Leptomeningeal Metastasis. Neuro-Oncology Advances(Suppl 1):i7-i8, 2019.
39. Seligman C, Lee EL, Tummala S, Kamiya-Matsuoka C.. Gram positive colonization of the Ommaya reservoir; treatment recommendations with clinical examples. Neuro Oncol 20(Suppl 6):vi146-vi147, 2018. e-Pub 2018.
40. Weathers SP, Kamiya-Matsuoka C, Dervin S, Yun C, Loghin M, O’Brien B, Harrison R, Yung WKA, Penas-Prado M, de Groot J.. Safety run-in results of a phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM). Neuro Oncol 20(suppl 6):vi9-vi-10, 2018. e-Pub 2018.
41. de Groot JF, Penas-Prado M, Mandel J, O’Brien B, Weathers SP, Loghin M, Kamiya-Matsuoka C, Zhou S, Colen R, Hunter K, Fuller G, Huse JT, Rao G, Weinberg J, Prabhu S, Ferguson S, Yuan Y, Vence L, Allison J, Sharma P, Heimberger.. A Window-of-opportunity clinical trial of pembrolizumab in recurrent glioblastoma patients. Neuron Oncology 20(Suppl 6):vi2, 2018.
42. Metrus NR, Daher A, Harrison RA, Majd N, Maraka S, Nam JY, Trevino C, Weathers SP, O’Brien B, Kamiya-Matsuoka C, Loghin M, Alfaro K, Hunter K, Yung WKA, de Groot J, Penas-Prado M.. Analysis of Challenges to Accrual in Clinical Trials for Newly Diagnosed Glioblastoma. Neuro Oncology 20(Suppl 6):vi141, 2018.
43. Hassan I, Kotrotsou A, Kamiya-Matsuoka C, Alfaro-Munoz KD, Elshafeey N, El Shafei N, Zinn P, de Groot JF, Colen R.. A radiomic-based MRI phenotype is uniquely associated with hypermutated genotype in gliomas. Cancer Research 78(13 Suppl):2955, 2018.
44. Santos-Pinheiro F, Gatson NT, Kamiya-Matsuoka C, Fuller G, Weinberg J, Tremont I, de Groot JF, Loghin ME.. Gliomatosis Cerebri: Predispositions and Predictors of Behavior. Neurology 90(15 Suppl), 2018.
45. Johnson J, Metrus N, Kamiya-Matsuoka C.. Glioblastoma that Arises from Tumefactive Multiple Sclerosis. Neurology 90(15 Suppl), 2018. e-Pub 2018.
46. Kamiya-Matsuoka C, Shaw K, Loghin ME, Penas-Prado M, O’Brien BJ, Weathers SP, Alfaro-Munoz KD, Yung WKA, de Groot JF.. The Natural Course of Hypermutator Gliomas. Journal of Clinical Oncology 36(Suppl 15), 2018.
47. Metrus N, Kamiya-Matsuoka C, Johnson J.. Paroxysmal Singultus as the result of Brainstem Histoplasmosis. Neurology 90(15):Suppl 5.128, 2018.
48. Penas-Prado M, Rezvani K, Weathers SP, Zhou S, Kamiya-Matsuoka C, O'Brien BJ, Loghin ME, Harrison RA, Pei BL, Ictech S, Hunter K, Yung WKA, de Groot JF, Shpall EJ, Heimberger AB.. A phase I/II clinical trial of autologous CMV-specific cytotoxic T cells (CMV-TC) for glioblastoma: Dose escalation results. Journal of Clinical Oncology 36(Suppl 15), 2018.
49. Hassan I, Kotrotsou A, Kamiya-Matsuoka C, Alfaro-Munoz KD, Elshafeey N, El Shafei N, Zinn P, de Groot JF, Colen R.. A unique MRI-based radiomic signature predicts hypermutated glioma genotype. Journal of Clinical Oncology 36(Supple 15), 2018.
50. Zinn PO, Hassan I, Kotrotsou A, Kamiya-Matsuoka C, Alfaro-Munoz K, Elshafeey N, Elshafeey N, de Groot JF, Colen RR.. Magnetic Resonance Imaging Vector Machine Learning Predicts the Glioma Hypermutation Phenotype. Congress of Neurological Surgeons, 2018.
51. Penas-Prado M, Weathers SP, Zhou S, Kamiya-Matsuoka C, O’Brien B, Loghin M, Harrison R, Pei BL, Ictech S, Hunter K, Yung WKA, de Groot J, Shpall EJ, Heimberger A, Rezvani K.. A Phase I/II Clinical Trial of Autologous CMV-Specific Cytotoxic T Cells (CMV-TC) for Glioblastoma: Dose Escalation and Correlative Results. Neuro Oncol 20(Suppl 6):vi2-vi3, 2018.
52. O’Brien B, de Groot JF, Kamiya-Matsuoka C, Weathers SP, Bacha J, Brown D, Steino A, Langlands J, Schwartz R, Kanekal S, Lopez L, Penas-Prado M.. Phase 2 Study of Dianhydrogalactitol (VAL-083) in Patients with MGMT-Unmethylated, Bevacizumab-Naïve Recurrent Glioblastoma. Neuro-Oncology 20(Suppl 6):vi17, 2018.
53. O’Brien B, de Groot JF, Kamiya-Matsuoka C, Weathers SP, Bacha J, Brown D, Steino A, Langlands J, Schwartz R, Kanekal S, Lopez L, Penas-Prado M.. Phase II Study of Dianhydrogalactitol (VAL-083) in Patients with Bevacizumab-Naïve Recurrent Glioblastoma, MGMT-Unmethylated. Cancer Res 78(Suppl 13), 2018.
54. Hassan I, Kotrotsou A, Kamiya-Matsuoka C, Alfaro-Munoz KD, Elshafeey N, Zinn P, de Groot JF, Colen R.. Increased mutation burden (Hypermutation) in gliomas is associated with a unique radiomic texture signature in magnetic resonance imaging. Neuro Oncol 19(Suppl 6):vi147-vi148, 2017. e-Pub 2017.
55. Pinnix CC, Chi L, Jabbour EJ, Milgrom SA, Smith GL, Daver N, Garg N, Cykowski MD, Fuller G, Cachia D, Kamiya-Matsuoka C, Woodman K, Dinardo C, Jain N, Kadia TM, Pemmaraju N, Ohanian M, Konopleva M, Kantarjian HM, Dabaja BS.. Dorsal column myelopathy following intrathecal chemotherapy for leukemia. Am J Hematol 92(2):155-160, 2017. PMID: 27874212.
56. Santos-Pinheiro F, Penas-Prado M, McCutcheon I, Waguespack S, Mahajan A, Brown P, Kamiya-Matsuoka C.. Pituitary carcinoma: The University of Texas MD Anderson Cancer Center experience. Journal of Clinical Oncology 35(suppl 15), 2017.
57. Nam J, Harrison RA, Weathers SP, Pillainayagam C, de Groot JF, Kamiya-Matsuoka C, Loghin ME, Penas-Prado M, Yung WKA, Li J, Ferguson SD, O'Brien BJ.. Association of clinical phenotype and treatment history with survival in adult brainstem glioblastoma. Journal of Clinical Oncology 35(Suppl 15), 2017.
58. Kamiya-Matsuoka C, Shaw K, Loghin ME, Penas-Prado M, O’Brien BJ, Weathers SP, Alfaro-Munoz KD, Yung WKA, de Groot JF.. The Natural Course of Hypermutator Gliomas. Neuro Oncol 19(6):vi179, 2017.
59. Gatson NN, Kamiya-Matsuoka C, Rodriguez-Linares Y, Pillainayagam C, Cachia D, Daher A, Chi T, Weinberg J, Tremont-Lukats IW, Fuller G, de Groot JF, Loghin M.. Rare-26. Gliomatosis, to be or not to cerebri: an evaluation of host systemic immune factors that potentially predispose to diffuse infiltrative glioma patterns. Neuro-Oncolgy 18(Suppl 6):vi165, 2016.
60. Yust-Katz S, Cachia D, Kamiya-Matsuoka C, Theeler BJ, Olar A, Penas-Prado M, Armstrong T, Gilbert M.. Ependymomas arising outside of the central nervous system: A case series. Neuro-Oncology 18(Suppl 6):vi162, 2016.
61. Daher A, Johnson JK, Kamiya-Matsuoka C, Thomas S, Woodman K.. Neurolymphomatosis and Anti-MAG Mononeuritis Multiplex in a Patient with Two Hematologic Malignancies. Neurology 86(16 Suppl):p6-284, 2016. e-Pub 2016.
62. Liao B, Kamiya-Matsuoka C, Smith RG, Ju H, Shanina E.. Carpal Tunnel Syndrome Assessment in Elderly Patients - Problems and Potential Solutions, 2015.
63. Cachia D, Kamiya-Matsuoka C, Pinnix CC, Chi L, Kantarjian HM, Cortes JE, Daver N, Woodman K. Myelopathy following intrathecal chemotherapy in adults: a single institution experience. J Neurooncol 122(2):391-8, 2015. e-Pub 2015. PMID: 25666482.
64. Liao B, Kamiya-Matsuoka C.. Atypical isolated nuclear oculomotor nerve syndrome: A diagnostic challenge. BMJ Case Rep, 2015. PMID: 25694634.
65. Kamiya-Matsuoka C, Liao B.. Atypical isolated nuclear oculomotor nerve syndrome: A diagnostic challenge 84(14):Supplement P1.031, 2015.
66. Mella DB, Kamiya-Matsuoka C, Liao B, Tummala S, de Groot JF.. Encephaloclastic cyst induced by intraventricular topotecan 84(14):Supplement P3.138, 2015.
67. Shah R, Kamiya-Matsuoka C, Liao B, Tummala S.. Electrographic Patterns In Patients With Posterior Reversible Encephalopathy Syndrome (PRES) And Seizures 84(14):Supplement P2.088, 2015.
68. Rengifo-Cam W, Kamiya-Matsuoka C, Nayfe R, Masaki T, Samadder J, Berstein E.. Expression of Csk is associated with its methylation status in colorectal cancer cells 148(4):S-181, Supplement 1, 2015.
69. Barata PC, Kamiya-Matsuoka C, Lee-Kim SH, Loghin ME, O’Brien BJ, Tremont-Lukats IW.. Outcomes after hospitalization in patients with recurrent glioblastoma 33:5s Supplement e13020, 2015.
70. Cachia D, Elshafeey NA, Kamiya-Matsuoka C, Hatami M, Alfaro-Munoz KD, Mandel JJ, Colen R, de Groot JF.. Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients 17(5):v154, 2015.
71. Kamiya-Matsuoka C, Cachia D, Olar A, Armstrong TS, Gilbert MR. Primary brain tumors and posterior reversible encephalopathy syndrome. Neurooncol Pract 1(4):184-190, 2014. e-Pub 2014. PMID: 26034631.
72. Kamiya-Matsuoka C, Cachia D, Waguespack SG, McCutcheon IE, Mahajan A, Brown PD, Groves MD, Penas-Prado M.. Temozolomide-based therapy for the management of progressive pituitary carcinoma. Neuro Oncol 16(suppl 5):v129, 2014.
73. Liao B, Kamiya-Matsuoka C, Fang X, Smith GR.. Refractory IgG4-related intracranial hypertrophic pachymeningitis. Neurol Neuroimmunol Neuroinflamm 1(4):e41, 2014. e-Pub 2014. PMID: 25364775.
74. Liao B, Kamiya-Matsuoka C, Fang X, Smith GR.. Refractory IgG4-related intracranial hypertrophic pachymeningitis. Neurology 82(10), 2014. e-Pub 2014.
75. Kamiya-Matsuoka C, Liao B, Gong Y, Chen M, Woodman K, Fowler N, Conrad C.. Primary Natural Killer/T-cell Lymphoma Presenting as Leptomeningeal Disease. Neurology 82(10):Supplement P7.029, 2014.
76. Kamiya-Matsuoka C, Liao B, Gong Y, Tremont-Lukats IW.. Primary Natural Killer/T-cell Lymphoma Presenting as Leptomeningeal Disease. EFNS European Journal of Neurology 21(1):104-387, 2014.
77. Hamza MA, Kamiya-Matsuoka C, de Groot JF.. Impact of adverse effects of bevacizumab on survival outcomes of patients with recurrent glioblastoma. J Clin Oncol 32(Suppl 2075):5, 2014.
78. Cachia D, Kamiya-Matsuoka C, Pinnix CC, Chi L, Kantarjian HM, Cortes JE, Daver N, Woodman K.. Myelopathy following intrathecal chemotherapy: a case series in adults 16(5):v26-v50, 2014.
79. Kamiya-Matsuoka C, Cachia D, Armstrong TS, Gilbert MR.. Primary Brain Tumors and Posterior Reversible Encephalopathy Syndrome 16(5):v26-v50, 2014.
80. Kamiya-Matsuoka C, Cachia D, Waguespack SG, McCutcheon IE, Mahajan A, Brown PD, Groves MD, Penas-Prado M.. Temozolomide-based therapy for the management of progressive pituitary carcinoma 16(5):v129, 2014.
81. Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S.. Atypical Neurological Complications of Ipilimumab Therapy in Patients with Metastatic Melanoma. Neurology 82(10 Suppl):P3-308, 2014.
82. Kamiya-Matsuoka C, Liao B, Gong Y, Chen M, Woodman K, Fowler N, Conrad C.. Primary Natural Killer/T-cell Lymphoma Presenting as Leptomeningeal Disease. Neurology 82(Suupl 10):260, 2014.
83. Garciarena P, Kamiya-Matsuoka C, Tremont IW, Amin HM, de Groot JF.. B lymphoblastic leukemia/lymphoma presenting as fifth and seventh cranial nerve palsy 80(1):Supplement P7.008, 2013.
84. Hormozdi B, Kamiya-Matsuoka C, Gildersleeve K, Woodman K.. Neurolymphomatosis: A case series of clinical manifestations, treatments, and outcomes 78(1):Supplement P4.187, 2012.
85. Paker AM, Kamiya-Matsuoka C, Chi L, Loghin ME.. Posterior reversible encephalopathy syndrome in cancer patients 78(1):Supplement P6.015, 2012.
86. Paker AM, Chi L, Kamiya-Matsuoka C, Loghin ME.. Posterior reversible encephalopathy syndrome in cancer patients 13(3):iii26–iii29, 2011.
87. Kamiya-Matsuoka C.. Perception of the Medical Students and Attending Physicians of the Major National University of San Marcos about Animal Experimentation, 2005.
88. Inga E, Lopez G, Kamiya-Matsuoka C.. Biological accidents in medical students of the Major National University of San Marcos: prevalence, mechanisms and risk factors, 2005.
89. Kamiya-Matsuoka C.. Anatomic variants of Celiac Trunk, 2003.
90. Kamiya-Matsuoka C.. Citoprotective effect of the epidermic growth factor in renal ischemia reperfusion injury, 2002.
91. Kamiya-Matsuoka C. Protein-Energetic Malnutrition of the mother during the prenatal and postnatal period produces alterations in the development of offspring’s brain, 2001.